Company: LIMN
Filing Date: 2025-07-28
Form Type: S-1/A
Source: 0001410578-25-001518
Chunk: 315

Company: Liminatus Pharma, Inc.
Filing Date: 2025-07-28
Form: S-1/A
Chunk 315
---
 subject to adjustment for applicable taxes, including, but not limited to, franchise tax, excise tax and income tax, for an aggregate redemption amount of $ 10,358,754. Following such redemptions, 406,609Public Shares remained outstanding. In January 2024, the Company recovered an excess redemption to shareholders in the amount of $ 294,669for federal tax payments that were due. On March 7, 2024, stockholders holding 119,572Public Shares properly exercised their right to redeem their shares for cash at a redemption price of approximately $ 10.58per share, adjusted for applicable taxes in the amount of $ 60,000, including, but not limited to, franchise tax, excise tax and income tax, for an aggregate redemption amount of $ 1,265,669. Following such redemptions, 287,037Public Shares remained outstanding. The redemptions were settled on April 2, 2024. On September 5, 2024, stockholders holding 48,107Public Shares properly exercised their right to redeem their shares for cash at a redemption price of approximately $ 11.17per share, subject to adjustment for applicable taxes, including, but not limited to, franchise tax, excise tax and income tax, for an aggregate redemption amount of $ 537,200. Following such redemptions, 238,930Public Shares remained outstanding. On December 20, 2024, stockholders holding 64,453public shares properly exercised their right to redeem their shares for cash at a redemption price of approximately $ 11.47per share, subject to adjustment for taxes payable from the trust account, for an aggregate redemption amount of approximately $ 739,195. Following such redemptions, 174,477Public Shares will remain outstanding. The redemptions were settled on February 3, 2025. Business Combination Agreement On November 30, 2022, Iris Acquisition Corp, a Delaware corporation (“we,” “our,” or “Iris”), Iris Parent Holding Corp., a Delaware corporation (“ParentCo”), Liminatus Pharma, LLC, a Delaware limited liability company (“Liminatus”), Liminatus Pharma Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of ParentCo (“Liminatus Merger Sub”), and SPAC Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of ParentCo (“SPAC Merger Sub” and together with Liminatus Merger